Drug Profile
CVT 4325
Alternative Names: CVT-4325Latest Information Update: 09 Sep 2008
Price :
$50
*
At a glance
- Originator CV Therapeutics
- Class Piperazines
- Mechanism of Action Partial fatty acid oxidation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Angina pectoris; Chronic heart failure; Myocardial ischaemia
Most Recent Events
- 09 Sep 2008 No development reported - Preclinical for Chronic heart failure in USA (unspecified route)
- 24 Apr 2006 No development reported - Preclinical for Angina pectoris in USA (unspecified route)
- 24 Apr 2006 No development reported - Preclinical for Myocardial ischaemia in USA (unspecified route)